Current Report Filing (8-k)
November 17 2022 - 4:11PM
Edgar (US Regulatory)
0001728328
false
A1
BC
0001728328
2022-11-17
2022-11-17
0001728328
dei:FormerAddressMember
2022-11-17
2022-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 17, 2022
INMED PHARMACEUTICALS INC.
(Exact Name of Company as Specified in Charter)
| British Columbia |
|
001-39685 |
|
98-1428279 |
|
(State or Other Jurisdiction
of
Incorporation) |
|
(Commission File
Number) |
|
(IRS Employer
Identification
No.) |
|
InMed Pharmaceuticals Inc.
Suite 310 - 815 W. Hastings Street,
Vancouver, B.C.
Canada |
|
V6C 1B4 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Company’s
telephone number, including area code: (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common Shares, no par value |
|
INM |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On November 14, 2022, the Company terminated the
Consulting Agreement for Brenda Edwards effective November 20, 2022. Ms. Edwards has been engaged on an interim consulting basis through
a placement agent whereby the Company paid the placement agency a monthly retainer and paid directly to Ms. Edwards an hourly rate for
her services. Ms. Edwards has served as the Company’s Interim Chief Financial Officer since April 1, 2022.
The Company’s Controller, Sarah Li, has
been promoted to Vice President of Accounting and Controller and Principal Accounting Officer. Ms. Li has served as the Company’s
controller since January 2020. Prior to that, she was Controller of GoldMining Inc. (TSX: GOLD) (NYSE American: GLDG) from March 2017
until September 2019.
The Company is currently in discussions to finalize
the engagement of interim financial leadership (CFO) consulting services.
Item 7.01 Regulation FD Disclosure.
On November 17, 2022, the Company issued a press
release announcing the termination of Ms. Edwards’ consulting agreement. A copy of the press release is furnished as Exhibit 99.1
hereto and is incorporated herein by reference.
The information set forth in this Item 7.01, including
Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth
in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
INMED PHARMACEUTICALS INC. |
| |
|
|
| Date: November 17, 2022 |
By: |
/s/ Eric A Adams |
| |
|
Eric A Adams
President & CEO |
2
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Oct 2024 to Nov 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Nov 2023 to Nov 2024
